Research programme: endomorphin analogues - Cytogel PharmaAlternative Names: EM-1; Endomorphin-1
Latest Information Update: 01 Nov 2011
At a glance
- Originator Tulane University
- Developer Cytogel
- Class Peptides
- Mechanism of Action Opioid mu receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 01 Nov 2011 Preclinical development is ongoing in USA
- 03 Dec 2008 Preclinical trials in Pain in USA (unspecified route)